# OnCo record trial-modernisation-roadmap (roadmap). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/roadmaps/trial-modernisation-roadmap/>
  a schema:CreativeWork ;
  onco:kind "roadmap" ;
  schema:identifier "trial-modernisation-roadmap" ;
  schema:name "Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on"@en ;
  schema:description "The randomised trial is how oncology knows what works, and it is slow, expensive and enrols fewer than one in ten patients. The roadmap is the set of designs and tools that keep the rigour while cutting the time, cost and exclusions: platform trials that never close, blood-test endpoints, remote consent, real-world data used honestly, and doses chosen by evidence."@en ;
  schema:url <https://onco.cc/roadmaps/trial-modernisation-roadmap/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/optimizing-dosage-human-prescription-drugs-and-biological-products-treatment-oncologic-diseases>, <https://www.stampedetrial.org/>, <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/conducting-clinical-trials-decentralized-elements> ;
  onco:related <https://onco.cc/collections/clinicaltrials-gov/>, <https://onco.cc/collections/flatiron-foundation-cgdb/>, <https://onco.cc/ideas/idea-tr1-standing-platform-per-cancer/>, <https://onco.cc/ideas/idea-tr2-perpetual-platforms/>, <https://onco.cc/ideas/idea-tr2-platform-single-ethics/>, <https://onco.cc/ideas/idea-reg-recovery-style-platform-repurposing/>, <https://onco.cc/ideas/idea-bio2-national-mrd-platform/>, <https://onco.cc/ideas/idea-bio1-resistance-platform-trial/>, <https://onco.cc/ideas/idea-tr2-bandit-allocation/>, <https://onco.cc/ideas/idea-bio2-rare-cancer-umbrella-platform/>, <https://onco.cc/ideas/idea-tr2-neoadjuvant-combo-platform/>, <https://onco.cc/ideas/idea-tr1-justify-every-exclusion/>, <https://onco.cc/ideas/idea-tr1-remote-consent-tele-screening/>, <https://onco.cc/ideas/idea-tr1-ehr-point-of-care-trial-alert/>, <https://onco.cc/ideas/idea-tr1-registry-embedded-randomisation/>, <https://onco.cc/ideas/idea-tr1-external-control-rulebook/>, <https://onco.cc/ideas/idea-tr1-post-approval-pragmatic-trial-in-excluded/>, <https://onco.cc/ideas/idea-tr1-mandatory-older-adult-cohort/>, <https://onco.cc/ideas/idea-tr1-diversity-plans-with-consequences/>, <https://onco.cc/ideas/idea-tr1-eligibility-impact-statement/>, <https://onco.cc/ideas/idea-tr1-ai-central-imaging-reads/>, <https://onco.cc/ideas/idea-tr1-target-trial-emulation-to-prioritise-rcts/>, <https://onco.cc/ideas/idea-tr1-validate-real-world-progression-endpoints/>, <https://onco.cc/ideas/idea-tr2-ctdna-mrd-qualification/>, <https://onco.cc/ideas/idea-bio2-neoadjuvant-biomarker-engine/>, <https://onco.cc/ideas/idea-tr1-window-of-opportunity-default/>, <https://onco.cc/ideas/idea-reg-generic-targeted-therapy-drup/>, <https://onco.cc/ideas/idea-reg-global-dose-optimisation-guideline/>, <https://onco.cc/ideas/idea-tr1-randomised-dose-comparison-before-pivotal/>, <https://onco.cc/ideas/idea-moon-pro-ctcae-in-every-pivotal-trial/>, <https://onco.cc/ideas/idea-tr1-win-ratio-net-benefit-endpoint/>, <https://onco.cc/ideas/idea-tr1-tolerability-estimands/>, <https://onco.cc/ideas/idea-tr1-surrogate-validation-programme/>, <https://onco.cc/ideas/idea-reg-conditional-approval-sunset/>, <https://onco.cc/ideas/idea-reg-confirmatory-trial-escrow/>, <https://onco.cc/ideas/idea-tr1-lmic-sites-in-pivotal-trials/>, <https://onco.cc/ideas/idea-tr1-pay-participants-for-time/>, <https://onco.cc/ideas/idea-tr1-protected-physician-time-for-enrolment/>, <https://onco.cc/ideas/idea-tr2-material-failure-disclosure/>, <https://onco.cc/ideas/idea-tr2-reversal-registry/>, <https://onco.cc/ideas/idea-reg-orbis-work-sharing/>, <https://onco.cc/roadmaps/global-access-roadmap/>, <https://onco.cc/roadmaps/diagnostics-roadmap/>, <https://onco.cc/roadmaps/prostate-roadmap/>, <https://onco.cc/ideas/idea-prostate-randomise-the-sequence-not-only-the-drugs/> ;
  onco:technologies <https://onco.cc/technologies/remote-patient-monitoring/>, <https://onco.cc/technologies/telemedicine-teleoncology/>, <https://onco.cc/technologies/ai-trial-matching/>, <https://onco.cc/technologies/digital-twins-trials/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/imaging-core-labs/>, <https://onco.cc/technologies/companion-diagnostic/>, <https://onco.cc/technologies/functional-drug-testing/> ;
  onco:companies <https://onco.cc/companies/swog/>, <https://onco.cc/companies/ecog-acrin/>, <https://onco.cc/companies/alliance-oncology/>, <https://onco.cc/companies/nrg-oncology/>, <https://onco.cc/companies/cctg/>, <https://onco.cc/companies/childrens-oncology-group/>, <https://onco.cc/companies/science-37/>, <https://onco.cc/companies/medidata/>, <https://onco.cc/companies/trinetx/>, <https://onco.cc/companies/flatiron-health/>, <https://onco.cc/companies/tempus/>, <https://onco.cc/companies/trial-library/>, <https://onco.cc/companies/massive-bio/> ;
  onco:institutions <https://onco.cc/institutions/nci/>, <https://onco.cc/institutions/fda-oce/>, <https://onco.cc/institutions/ema/>, <https://onco.cc/institutions/tata-memorial/> ;
  onco:terms <https://onco.cc/terms/real-world-evidence/>, <https://onco.cc/terms/accelerated-approval/>, <https://onco.cc/terms/tumour-agnostic/>, <https://onco.cc/terms/project-orbis/>, <https://onco.cc/terms/surrogate-endpoint/> ;
  onco:trials <https://onco.cc/trials/stampede/>, <https://onco.cc/trials/pediatric-match/>, <https://onco.cc/trials/dynamic/>, <https://onco.cc/trials/circulate-japan/>, <https://onco.cc/trials/serena-6/>, <https://onco.cc/trials/imvigor011/>, <https://onco.cc/trials/niche-2/>, <https://onco.cc/trials/phergain/>, <https://onco.cc/trials/keynote-522/>, <https://onco.cc/trials/add-aspirin/>, <https://onco.cc/trials/challenge/>, <https://onco.cc/trials/persephone/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-trial-enrolment/>, <https://onco.cc/bottlenecks/b-trial-design/>, <https://onco.cc/bottlenecks/b-trial-diversity/>, <https://onco.cc/bottlenecks/b-real-world-evidence/>, <https://onco.cc/bottlenecks/b-dose-optimisation/>, <https://onco.cc/bottlenecks/b-negative-results/>, <https://onco.cc/bottlenecks/b-regulatory-fragmentation/>, <https://onco.cc/bottlenecks/b-aging-comorbidity/> .